Orchid Pharma shares rose 1.10% to ₹723.50 following the release of its Q4 FY26 financial results. According to reports from Business Standard, the Chennai-based pharmaceutical company reported a 6.68% increase in consolidated net profit to ₹23.78 crore for the fourth quarter ended March 2026, compared with ₹22.29 crore in the corresponding quarter last year. Revenue from operations showed marginal growth, rising to ₹237.61 crore in Q4 FY26 from ₹237.48 crore posted in the same period last year.
The company's profit before exceptional items and tax stood at ₹22.25 crore, representing a 16.55% increase from ₹19.09 crore reported in Q4 FY25. As reported by Business Standard, the company recorded exceptional items of ₹0.54 crore during the quarter. The improved profitability metrics despite flat revenue growth indicate enhanced operational efficiency and cost management during the quarter.
For the full financial year FY26, Orchid Pharma reported a 79.37% decline in consolidated net profit to ₹20.55 crore, while revenue from operations fell 11.99% year-on-year to ₹811.33 crore compared with FY25. According to the company's disclosure, this contrasts sharply with the quarterly performance, suggesting seasonal or operational factors may have impacted the annual results.
Orchid Pharma operates as a Chennai-based pharmaceutical company engaged in the development, manufacture and marketing of bulk actives, formulations and nutraceuticals. As reported by Business Standard, the company has an export presence across over 40 countries, positioning it as a significant player in the global pharmaceutical market with diversified geographical revenue streams.
